Variation in Basal Serum Cortisol Levels During Treatment of Oral Lichen Planus With 0.5% Triamcinolone Acetonide Mouthrinses: A Prospective Observational Study

Elena Blanco‐Aguilera, Pilar Gándara‐Vila, Valeria Sanmartín‐Barragáns, Javier Rodríguez‐García, Xabier Marichalar‐Mendía, Antonio Blanco‐Aguilera, Alejandro I. Lorenzo‐Pouso, Eva Otero‐Rey, Andrés Blanco‐Carrión
Oral Diseases · Wiley · 2026-11-19 · DOI: 10.1111/odi.70568

Abstract

ABSTRACT Objective To evaluate changes in basal serum cortisol levels in patients with atrophic‐erosive oral lichen planus (OLP) and oral lichenoid lesion (OLL) treated with 0.5% triamcinolone acetonide mouthrinses and to assess the occurrence of clinical manifestations associated with adrenal dysfunction. Methods A prospective observational study was conducted in 68 patients with clinically and histopathologically confirmed atrophic‐erosive OLP or OLL. Participants received 0.5% triamcinolone acetonide mouthrinses following a tapering regimen over 3 months. Basal serum cortisol levels were measured at baseline, after 30 days, and after 90 days of treatment. Clinical and demographic variables and treatment‐related adverse effects were analyzed. Results Mean basal serum cortisol levels decreased from 17.05 ± 4.38 μg/dL at baseline to 8.79 ± 7.34 μg/dL after 1 month of treatment. Following dose tapering, serum cortisol levels (SCL) partially recovered to 11.94 ± 6.44 μg/dL at 3 months. No clinical manifestations of adrenal insufficiency were observed. Baseline SCL were significantly associated with serum cortisol concentrations after 1 month ( r = 0.34; p < 0.05). Older patients exhibited smaller hormonal fluctuations during treatment. Conclusions Triamcinolone acetonide induced a transient reduction in SCL without clinically relevant adrenal dysfunction, suggesting a limited systemic impact when administered a tapering regimen.

Read at publisher →

Similar articles